← Back
Data updated: Mar 10, 2026
BIOCON BIOLOGICS INC
OncologyImmunologyMetabolic
BIOCON BIOLOGICS INC is a biotechnology company focused on Oncology, Immunology, Metabolic.
2024
Since
6
Drugs
-
Trials
9
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
YESAFILI 2026-01-13
Manufacturing (CMC)
YESINTEK 2026-01-07
AUKELSO 2025-10-29
Efficacy
AUKELSO 2025-09-16
KIRSTY 2025-07-15
Type 5 - New Formulation or New Manufacturer
YESINTEK 2025-04-30
JOBEVNE 2025-04-09
Type 5 - New Formulation or New Manufacturer
YESINTEK 2024-11-29
Type 2 - New Active Ingredient
YESAFILI 2024-05-20
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 45%
3 drugs
Immunology 25%
1 drugs Phase 3: 1
Metabolic 15%
1 drugs
Gastroenterology 15%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Metabolic
Merck big-pharma
Oncology, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Metabolic
ASTELLAS specialty
Oncology, Gastroenterology, Metabolic, Immunology